Provided by Tiger Trade Technology Pte. Ltd.

Taysha Gene Therapies, Inc.

5.97
-0.1200-1.97%
Post-market: 5.970.00000.00%16:04 EDT
Volume:1.21M
Turnover:7.28M
Market Cap:1.95B
PE:-14.47
High:6.08
Open:6.02
Low:5.83
Close:6.09
52wk High:7.30
52wk Low:2.71
Shares:325.83M
Float Shares:233.00M
Volume Ratio:0.40
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4126
EPS(LYR):-0.3409
ROE:-47.05%
ROA:-23.82%
PB:5.02
PE(LYR):-17.51

Loading ...

U.S. Small Caps Finish Mixed As Taysha Gene Therapies Leads, BRP Lags

Dow Jones
·
Apr 16

Buy Rating on Taysha Gene Therapies Driven by Strong Leadership, Strategic Positioning, and Attractive Risk‑Reward Upside

TIPRANKS
·
Apr 15

Taysha Gene Therapies President Sukumar Nagendran disposes 200,000 shares for $892,000

Reuters
·
Apr 14

Taysha Gene Therapies Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Apr 06

Taysha Gene Therapies price target raised to $17 from $14 at Canaccord

TIPRANKS
·
Apr 06

Taysha grants 300,000 RSUs under Nasdaq inducement plan for new hires

Reuters
·
Apr 03

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 03

Stock Track | Taysha Gene Therapies Soars 5.33% Intraday After Cantor Fitzgerald Issues Buy Rating

Stock Track
·
Mar 25

Taysha Gene Therapies (TSHA) Receives a Buy from Cantor Fitzgerald

TIPRANKS
·
Mar 25

Should Rett Breakthrough Status and Pivotal Trial Progress Require Action From Taysha Gene Therapies (TSHA) Investors?

Simply Wall St.
·
Mar 23

Taysha Gene Therapies (TSHA) Receives a Buy from Wells Fargo

TIPRANKS
·
Mar 22

Taysha Gene Therapies Advances Rett Program As Valuation Draws Investor Focus

Simply Wall St.
·
Mar 22

Taysha Gene Therapies Signals Momentum in Earnings Call

TIPRANKS
·
Mar 20

Taysha Gene Therapies Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 20

Analysts Are Bullish on These Healthcare Stocks: Collegium Pharmaceutical (COLL), Taysha Gene Therapies (TSHA)

TIPRANKS
·
Mar 20

Chardan Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)

TIPRANKS
·
Mar 20

Taysha Gene Therapies Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 19

Stock Track | Taysha Gene Therapies Soars 6.52% in Pre-market on Earnings Beat and Clinical Progress

Stock Track
·
Mar 19

Taysha Gene Therapies reports 2025 EPS (34c), consensus (34c)

TIPRANKS
·
Mar 19

Earnings Flash (TSHA) Taysha Gene Therapies Posts 2025 Revenue $9.8M, vs. FactSet Est of $5.9M

MT Newswires Live
·
Mar 19